Table 2.

Effect of rIL-18 on Th1-mediated resistance of caspase 1−/− mice to candidiasis

Treatment103CFU/kidneysaCytokine productionb
IFN-γIL-12p70
None4,532 ± 75481 ± 27<0.1
rIL-18c 1,785 ± 540e 168 ± 34e 5.89 ± 1.0e
rIL-18d 1,207 ± 365e 149 ± 38e 6.52 ± 0.8e
rIL-12c 4,032 ± 54094 ± 12<0.1
rIL-12d 2,671 ± 481e 159 ± 27e 2.01 ± 0.8e
  • a Caspase 1−/− mice were infected i.v. with 106 cells of PCA-2 and reinfected with 106 cells of CA-6 C. albicans, 14 days later. Data are shown as CFU (means ± SEs) in the kidneys, at 2 weeks after reinfection (n = 12).

  • b Cytokine content (nanograms per milliliter) in the culture supernatants of antigen-stimulated CD4+splenocytes (IFN-γ) or in the blood (IL-12p70), at 2 weeks after reinfection, as assessed by cytokine-specific ELISA (n= 12).

  • c Murine rIL-18, 1 μg/injection, or rIL-12, 10 ng/injection, was administered i.p. on the day of PCA-2 infection and 1 and 3 days later.

  • d rIL-18, 1 μg/dose, or rIL-12, 10 ng/dose, was administered i.p. on the day of reinfection with CA-6 and 1 and 3 days later.

  • e P < 0.05 (cytokine-treated versus untreated mice).